Early progression of disease as a predictor of survival in chronic lymphocytic leukemia

Author:

Ahn Inhye E.1,Farber Charles M.2,Davids Matthew S.3,Grinblatt David L.4,Kay Neil E.5,Lamanna Nicole6,Mato Anthony7,Nabhan Chadi8,Kiselev Pavel9,Swern Arlene S.9,Flick E. Dawn10,Sullivan Kristen11,Sharman Jeff P.12,Flowers Christopher R.13

Affiliation:

1. Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD;

2. Summit Medical Group, MD Anderson Cancer Center, Morristown, NJ;

3. Dana-Farber Cancer Institute, Boston, MA;

4. NorthShore University HealthSystem, Evanston, IL;

5. Division of Hematology, Mayo Clinic, Rochester, MN;

6. Leukemia Service, Division of Hematology and Oncology, Department of Medicine, New York-Presbyterian/Columbia University Medical Center, New York, NY;

7. Center for Chronic Lymphocytic Leukemia, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;

8. Cardinal Health, Dublin, OH;

9. Celgene Corporation, Summit, NJ;

10. Celgene Corporation, San Francisco, CA;

11. Celgene Corporation, Overland Park, KS;

12. Willamette Valley Cancer Institute, US Oncology, Springfield, OR; and

13. Winship Cancer Institute, Emory University, Atlanta, GA

Abstract

Key Points Early progression of disease within 2 years of initial therapy independently predicts inferior survival in CLL. Early progression of disease is a robust clinical end point and a useful posttreatment risk stratification tool.

Publisher

American Society of Hematology

Subject

Hematology

Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3